Rifaximin, a non-absorbable antibiotic, produces a modest but statistically significant improvement in global irritable bowel syndrome symptoms and bloating in patients with irritable bowel syndrome without constipation, with a number needed to treat of approximately 11 for symptom relief, and is recommended by clinical guidelines despite uncertain effects on microbiome composition.

Source: Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications

What the research says

Roughly balanced

Support and challenge are close. The picture may shift as more studies come in.

Supports

2score

Challenges

0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect

1 study reviewed

In plain English

Rifaximin, an antibiotic that stays in the gut, has been shown in studies to slightly reduce overall symptoms and bloating in people with irritable bowel syndrome who do not have constipation, with about 11 people needing to take it for one person to experience relief. Clinical guidelines recommend its use even though its impact on gut bacteria is not well understood.

See the scientific wording

Rifaximin, a non-absorbable antibiotic, provides modest but statistically significant improvement in global IBS symptoms and bloating in patients with IBS without constipation, with a number needed to treat of approximately 11 for symptom relief, and is recommended by clinical guidelines despite uncertain effects on microbiome composition.

Why this might work

Rifaximin reduces the number of certain bacteria in the gut that produce harmful substances like hydrogen sulfide and excess bile acids. This helps the gut lining heal and become less leaky, which stops immune cells from getting overactive. As a result, nerves in the gut stop sending too many pain signals, and the gut moves more normally, which reduces bloating and overall discomfort.

Supported mechanismbased on 1 study

What the research says

1 study

Study: Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications
This study says rifaximin is one of the few approved treatments for IBS, even though we’re not totally sure how it works on gut bacteria. That matches the claim that it helps some people feel better.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.